Substance dependence and remission in schizophrenia: A comparison of schizophrenia and affective disorders
- PMID: 19375237
- PMCID: PMC3607082
- DOI: 10.1016/j.addbeh.2009.03.023
Substance dependence and remission in schizophrenia: A comparison of schizophrenia and affective disorders
Abstract
The present study examined psychiatric functioning, substance use and consequences, and motivation to change in people with schizophrenia and affective disorders and current or remitted cocaine dependence. Data were collected as part of a naturalistic, longitudinal study examining substance use, motivation to change, and the process of change in people with schizophrenia and affective disorders who were currently dependent or in remission from cocaine dependence. We examined the following questions: (1) Do those in remission show better psychiatric functioning than those who are currently dependent? (2) How do people with schizophrenia and current cocaine dependence differ in terms of substance use and consequences from people with schizophrenia in remission and people with affective disorders and current drug dependence? (3) What internal factors and external factors are associated with changes in substance use in schizophrenia and how do these compare to those in nonpsychotic affective disorders? Results indicated that people with schizophrenia and current dependence reported higher levels of positive and negative symptoms than those in remission. Remission status was related to less use of other drugs, fewer days of drug problems, less distress from drug problems, and more lifetime drug-related consequences. Those with current dependence reported more days of drinking and drinking to intoxication, as well as higher rates of current alcohol use disorders than the remitted group. When compared to those with affective disorders and cocaine dependence, those with schizophrenia and current dependence reported fewer days of problems associated with their drug use, less distress from drug problems, and fewer recent and lifetime consequences associated with their drug use. The schizophrenia dependent group generally showed the lowest readiness to change, fewest efforts being made to change, and lowest confidence in the ability to change. Implications of these findings are discussed.
Figures
Similar articles
-
Neurocognitive characteristics of individuals with schizophrenia and cocaine dependence: comparison of currently dependent and remitted groups.J Nerv Ment Dis. 2009 Aug;197(8):631-4. doi: 10.1097/NMD.0b013e3181b08bf4. J Nerv Ment Dis. 2009. PMID: 19684503 Free PMC article.
-
Application of the Transtheoretical Model of change: psychometric properties of leading measures in patients with co-occurring drug abuse and severe mental illness.Addict Behav. 2008 Aug;33(8):1021-30. doi: 10.1016/j.addbeh.2008.03.012. Epub 2008 Apr 8. Addict Behav. 2008. PMID: 18485611 Free PMC article.
-
[Cannabis and schizophrenia: demographic and clinical correlates].Encephale. 2003 Jan-Feb;29(1):11-7. Encephale. 2003. PMID: 12640322 French.
-
Relationship of cocaine and other substance dependence to well-being of high-risk psychiatric patients.Psychiatr Serv. 1998 Jul;49(7):935-40. doi: 10.1176/ps.49.7.935. Psychiatr Serv. 1998. PMID: 9661229
-
Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders.Psychiatr Serv. 2003 Oct;54(10):1395-401. doi: 10.1176/appi.ps.54.10.1395. Psychiatr Serv. 2003. PMID: 14557527
Cited by
-
Lifetime trauma, subjective distress, substance use, and PTSD symptoms in people with severe mental illness: comparisons among four diagnostic groups.Community Ment Health J. 2013 Dec;49(6):728-32. doi: 10.1007/s10597-013-9620-8. Epub 2013 Jun 29. Community Ment Health J. 2013. PMID: 23812793
-
N-Methyl-d-aspartate receptor co-agonist availability affects behavioral and neurochemical responses to cocaine: insights into comorbid schizophrenia and substance abuse.Addict Biol. 2019 Jan;24(1):40-50. doi: 10.1111/adb.12577. Epub 2017 Nov 23. Addict Biol. 2019. PMID: 29168271 Free PMC article.
-
Predictors of initiation and engagement in substance abuse treatment among individuals with co-occurring serious mental illness and substance use disorders.Addict Behav. 2011 May;36(5):439-47. doi: 10.1016/j.addbeh.2010.12.001. Epub 2010 Dec 10. Addict Behav. 2011. PMID: 21196081 Free PMC article. Clinical Trial.
-
Executive Functioning in Men with Schizophrenia and Substance Use Disorders. Influence of Lifetime Suicide Attempts.PLoS One. 2017 Jan 18;12(1):e0169943. doi: 10.1371/journal.pone.0169943. eCollection 2017. PLoS One. 2017. PMID: 28099526 Free PMC article.
-
Health outcomes and service use patterns associated with co-located outpatient mental health care and alcohol and other drug specialist treatment: A systematic review.Drug Alcohol Rev. 2023 Jul;42(5):1195-1219. doi: 10.1111/dar.13651. Epub 2023 Apr 4. Drug Alcohol Rev. 2023. PMID: 37015828 Free PMC article.
References
-
- Alterman AI, Erdlen DL, Laporte DL, Erdlen FR. Effects of illicit drug use in an inpatient psychiatric setting. Addictive Behaviors. 1982;7(3):231–242. - PubMed
-
- Bai YM, Lin CC, Hu PG, Yeh HS. Risk factors for substance use disorders among inpatients with major affective disorders in Taiwan Chinese. General Hospital Psychiatry. 1998;29(6):377–380. - PubMed
-
- Barbee JG, Clark PD, Crapanzano MS, Heintz GC, Kehoe CE. Alcohol and substance abuse among schizophrenic patients presenting to an emergency psychiatric service. Journal of Nervous and Mental Disease. 1989;177:400–407. - PubMed
-
- Bellack AS, Bennett ME, Gearon JS,, Brown CH, Yang Y. A randomized clinical trial of a new behavioral intervention for drug abuse in people with severe and persistent mental illness. Archives of General Psychiatry. 2006;63:426–432. - PubMed
-
- Bellack AS, DiClemente CC. Treating substance abuse among patients with schizophrenia. Psychiatric Services. 1999;50:75–80. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical